Replies to Post #10187 onDendreon Corp fka DNDNQ

Replies to post #10187 on Dendreon Corp fka DNDNQ

Replies to #10187 on Dendreon Corp fka DNDNQ

12/27/12 4:37 PM

#10188 RE: jaydubs #10187

That’s an easy one: Provenge isn’t selling well and there is increased competition in the prostate-cancer market.

01/02/13 10:19 AM

#10194 RE: jaydubs #10187

It did go above $50...And then completely collapsed. I've found it to be a great buy though, paying under $5/share :)

Looking for big gains in 2013.